期刊
LEUKEMIA & LYMPHOMA
卷 58, 期 12, 页码 2811-2814出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1315115
关键词
Lymphoid leukemia; pharmacotherapeutics; lymphoma and Hodgkin disease
The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities who are representative of the majority of patients with CLL. This is especially complex in the case of ibrutinib. Many anticoagulants have potential for pharmacological interaction with ibrutinib, and ibrutinib itself has antiplatelet properties. Use of ibrutinib therapy in these patients mandates review and revision of the need for anticoagulation and best anticoagulant to use. Herein, we review the current knowledge of the metabolism of common anticoagulants and how they may interact with ibrutinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据